ABSTRACT
During the past several years much attention has been focused on peptidyl and nonpeptidyl growth hormone (GH) secretagogues (GHSs). Such an interest can be primarily ascribed to their promising therapeutic application both in animals and humans, but also to their use in fundamental research to better understand their mechanism of action, especially their interaction with specific receptors. In 1984, a synthetic hexapeptide (His-n-Trp-Aia-Trp-n-Phe-Lys-NH2) acting as a potent GHS termed growth hormone-releasing peptide (GHRP)-6 was developed that bound to a receptor different from a specific GH receptor (1).
